| Autor: |
Zabotti, Alen, Cabas, Nicola, Giovannini, Ivan, Guella, Silvia, Cereser, Lorenzo, Zuiani, Chiara, Stinco, Giuseppe, Quartuccio, Luca, Errichetti, Enzo |
| Předmět: |
|
| Zdroj: |
Clinical, Cosmetic & Investigational Dermatology; Jul2024, Vol. 17, p1553-1556, 4p |
| Abstrakt: |
This article discusses the efficacy of bimekizumab (BKZ) in treating psoriatic arthritis (PsA) patients who have not responded to previous biological treatments. The study included seven patients with active and biologics-refractory PsA. Results showed that BKZ led to significant joint improvement and disease activity reduction in the majority of patients, including those who had previously failed other IL-17A inhibitors. The treatment also showed potential for reducing pain and improving the patients' perception of their disease. However, the study had limitations in terms of sample size and follow-up duration, so further research is needed to confirm these findings. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
